ESR1 and breast carcinoma: To address this critical issue, a cell line-specific ODE model for ER+ and PI3K inhibitor-resistant breast cancer was developed to identify potential therapeutic drug combinations to increase drug sensitivity and overcome drug resistance (Gómez Tejeda Zañudo et al. 2021).